RxDoctor Payments Data

Henry Beecher, MD

Gastroenterology · Stamford, CTNPI 1396949582

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.9% of the total across 935 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations.

$18,553in general payments, 2019–2025

Across 935 payments — averaging $19.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$4K
  • Johnson & Johnson$2K
  • Pfizer$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Gilead$873
  • plus $6K from 35 others

What the payments were for

  • Food & beverage$18,540100%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,553 in reported general payments places this provider in the 85th percentile of 326 gastroenterology providers in Connecticut.

See all gastroenterology providers in Connecticut

Medicare billing

Part B allowed, 2024
$113,202
Medicare patients
402
Services billed
765

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase20$58,399
ViberziEluxadoline19$26,827
LinzessLinaclotide16$20,971
DexilantDexlansoprazole15$13,887
Mesalamine23$9,999
Omeprazole200$4,901
Dexlansoprazole DrDexlansoprazole11$4,116
Pantoprazole Sodium188$2,847
Dicyclomine Hcl31$889
Famotidine44$848
Metoclopramide Hcl11$115
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine12$76
Prednisone15$53

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Viberzi, Linzess$3,761$106,19755 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$1,435$13,88715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 326 gastroenterology providers in Connecticut.

Other gastroenterology in Stamford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →